NASDAQ:CRBP Corbus Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.54 +0.04 (+2.67 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range$1.39Now: $1.54▼$1.5950-Day Range$1.51MA: $6.03▼$9.3852-Week Range$1.39Now: $1.54▼$9.78Volume4.96 million shsAverage Volume2.07 million shsMarket Capitalization$125.84 millionP/E RatioN/ADividend YieldN/ABeta1.55 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.2 Analyst's Opinion Consensus RatingCorbus Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 4 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.72, Corbus Pharmaceuticals has a forecasted upside of 1,635.2% from its current price of $1.54.Amount of Analyst CoverageCorbus Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesCorbus Pharmaceuticals has received 411 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCorbus Pharmaceuticals has received 270 “underperform” votes. (Add your “underperform” vote.)Community SentimentCorbus Pharmaceuticals has received 60.35% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals and other stocks. Vote “Outperform” if you believe CRBP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRBP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCorbus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorbus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corbus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.20% of the stock of Corbus Pharmaceuticals is held by insiders.Percentage Held by Institutions55.85% of the stock of Corbus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Corbus Pharmaceuticals are expected to grow in the coming year, from ($1.67) to ($1.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corbus Pharmaceuticals is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corbus Pharmaceuticals is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorbus Pharmaceuticals has a P/B Ratio of 15.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.2Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.77 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRBP Previous Symbol CUSIPN/A CIK1595097 Webwww.corbuspharma.com Phone617-963-0100Debt Debt-to-Equity RatioN/A Current Ratio2.09 Quick Ratio2.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$36.14 million Price / Sales3.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book15.40Profitability EPS (Most Recent Fiscal Year)($1.12) Net Income$-71,450,000.00 Net Margins-1,596.42% Return on Equity-430.79% Return on Assets-164.13%Miscellaneous Employees141 Outstanding Shares81,712,000Market Cap$125.84 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $1.54 +0.04 (+2.67 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CRBP News and Ratings via Email Sign-up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter. Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions How has Corbus Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)? Corbus Pharmaceuticals' stock was trading at $4.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CRBP shares have decreased by 62.6% and is now trading at $1.54. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Corbus Pharmaceuticals? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Corbus Pharmaceuticals. When is Corbus Pharmaceuticals' next earnings date? Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Corbus Pharmaceuticals. How were Corbus Pharmaceuticals' earnings last quarter? Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) released its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by $0.13. The biopharmaceutical company had revenue of $0.29 million for the quarter, compared to analysts' expectations of $3.90 million. Corbus Pharmaceuticals had a negative return on equity of 430.79% and a negative net margin of 1,596.42%. View Corbus Pharmaceuticals' earnings history. What price target have analysts set for CRBP? 9 brokers have issued 1 year target prices for Corbus Pharmaceuticals' stock. Their forecasts range from $2.50 to $112.00. On average, they expect Corbus Pharmaceuticals' share price to reach $26.72 in the next twelve months. This suggests a possible upside of 1,635.2% from the stock's current price. View analysts' price targets for Corbus Pharmaceuticals. Who are some of Corbus Pharmaceuticals' key competitors? Some companies that are related to Corbus Pharmaceuticals include Clovis Oncology (CLVS), Assembly Biosciences (ASMB), Ocular Therapeutix (OCUL), Homology Medicines (FIXX), Albireo Pharma (ALBO), Mirum Pharmaceuticals (MIRM), Ardelyx (ARDX), Dynavax Technologies (DVAX), Neoleukin Therapeutics (NLTX), G1 Therapeutics (GTHX), Humanigen (HGEN), Crinetics Pharmaceuticals (CRNX), Aprea Therapeutics (APRE), Atreca (BCEL) and Tricida (TCDA). View all competitors. What other stocks do shareholders of Corbus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Canopy Growth (CGC), KushCo (KSHB) and Inovio Pharmaceuticals (INO). Who are Corbus Pharmaceuticals' key executives? Corbus Pharmaceuticals' management team includes the following people: Dr. Yuval Cohen, CEO & Director (Age 45, Pay $810.55k)Mr. Sean F. Moran CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 62, Pay $520k)Dr. Barbara White, Head of Research & Chief Medical Officer (Age 70, Pay $570.7k)Dr. Robert Paul Discordia Ph.D., Chief Operating Officer (Age 56)Ted Jenkins, Sr. Director of Investor Relations & Communications What is Corbus Pharmaceuticals' stock symbol? Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP." Who are Corbus Pharmaceuticals' major shareholders? Corbus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.37%), Point72 Asset Management L.P. (1.84%), Pinnacle Associates Ltd. (1.47%), Nuveen Asset Management LLC (0.94%), Tekla Capital Management LLC (0.46%) and Russell Investments Group Ltd. (0.43%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, Craig Stuart Millian, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran and Yuval Cohen. View institutional ownership trends for Corbus Pharmaceuticals. Which major investors are selling Corbus Pharmaceuticals stock? CRBP stock was sold by a variety of institutional investors in the last quarter, including AdvisorShares Investments LLC, Raymond James Financial Services Advisors Inc., Virtus ETF Advisers LLC, Pinnacle Associates Ltd., Aries Wealth Management, Sawtooth Solutions LLC, AE Wealth Management LLC, and Bank of Montreal Can. View insider buying and selling activity for Corbus Pharmaceuticals. Which major investors are buying Corbus Pharmaceuticals stock? CRBP stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Nuveen Asset Management LLC, Tekla Capital Management LLC, Swiss National Bank, UBS Group AG, PDT Partners LLC, SG Americas Securities LLC, and Jacobs Levy Equity Management Inc.. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Barbara White, Craig Stuart Millian, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran, and Yuval Cohen. View insider buying and selling activity for Corbus Pharmaceuticals. How do I buy shares of Corbus Pharmaceuticals? Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Corbus Pharmaceuticals' stock price today? One share of CRBP stock can currently be purchased for approximately $1.54. How big of a company is Corbus Pharmaceuticals? Corbus Pharmaceuticals has a market capitalization of $125.84 million and generates $36.14 million in revenue each year. The biopharmaceutical company earns $-71,450,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Corbus Pharmaceuticals employs 141 workers across the globe. What is Corbus Pharmaceuticals' official website? The official website for Corbus Pharmaceuticals is www.corbuspharma.com. How can I contact Corbus Pharmaceuticals? Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected] This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
